regorafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 4654 755037-03-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • regorafenib monohydrate
  • Stivarga
  • regorafenib
  • regorafenib hydrate
  • anhydrous regorafenib
  • BAY 73-4506
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis and tumor immunity. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl and CSF1R at concentrations of regorafenib that have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model and inhibition of tumor growth in several mouse xenograft models including some for human colorectal carcinoma, gastrointestinal stromal and hepatocellular carcinoma. Regorafenib also demonstrated anti-metastatic activity in a mouse xenograft model and two mouse orthotopic models of human colorectal carcinoma.
  • Molecular weight: 482.82
  • Formula: C21H15ClF4N4O3
  • CLOGP: 4.88
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.67
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.12 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 26, 2013 EMA
Sept. 27, 2012 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1133.27 26.32 340 11216 19758 50573810
Dysphonia 417.76 26.32 195 11361 38697 50554871
Decreased appetite 245.93 26.32 264 11292 200659 50392909
Off label use 241.26 26.32 405 11151 474021 50119547
Metastases to lung 158.87 26.32 68 11488 10952 50582616
Fatigue 153.64 26.32 428 11128 707173 49886395
Blister 107.16 26.32 114 11442 85304 50508264
Hyperkeratosis 106.75 26.32 41 11515 4994 50588574
Skin exfoliation 106.12 26.32 76 11480 33536 50560032
Asthenia 102.58 26.32 225 11331 318817 50274751
Diarrhoea 101.63 26.32 329 11227 588147 50005421
Pyrexia 98.13 26.32 246 11310 379957 50213611
Metastases to liver 96.37 26.32 59 11497 20045 50573523
Carcinoembryonic antigen increased 96.16 26.32 28 11528 1446 50592122
Hypertension 91.78 26.32 169 11387 211034 50382534
Blood bilirubin increased 91.08 26.32 68 11488 31970 50561598
Pain in extremity 90.55 26.32 195 11361 272670 50320898
Neuropathy peripheral 89.00 26.32 110 11446 96647 50496921
Stomatitis 75.71 26.32 104 11452 101240 50492328
Oral pain 75.34 26.32 55 11501 24978 50568590
Dehydration 73.85 26.32 128 11428 152321 50441247
Weight decreased 70.89 26.32 156 11400 221089 50372479
Dry skin 65.68 26.32 64 11492 43127 50550441
Rash 65.00 26.32 233 11323 437238 50156330
Blood pressure increased 64.74 26.32 112 11444 133020 50460548
Platelet count decreased 62.97 26.32 95 11461 100631 50492937
Hepatic function abnormal 54.56 26.32 51 11505 32630 50560938
Hospitalisation 51.12 26.32 70 11486 67867 50525701
Drug ineffective 50.90 26.32 68 11488 819265 49774303
Disseminated intravascular coagulation 50.09 26.32 37 11519 17098 50576470
Condition aggravated 47.45 26.32 6 11550 297052 50296516
Skin fissures 45.56 26.32 27 11529 8641 50584927
Erythema 45.41 26.32 102 11454 146312 50447256
Mucosal inflammation 44.06 26.32 50 11506 40092 50553476
Skin toxicity 43.08 26.32 20 11536 3893 50589675
Plantar erythema 42.86 26.32 10 11546 213 50593355
Abdominal pain 42.15 26.32 134 11422 236094 50357474
Gait inability 42.14 26.32 47 11509 36980 50556588
Tumour marker increased 40.33 26.32 19 11537 3821 50589747
Dry mouth 39.44 26.32 56 11500 56122 50537446
Colorectal cancer metastatic 39.04 26.32 11 11545 504 50593064
Exercise tolerance decreased 38.90 26.32 20 11536 4854 50588714
Palmoplantar keratoderma 37.92 26.32 8 11548 105 50593463
Hepatic encephalopathy 35.57 26.32 24 11532 9612 50583956
Colon cancer 35.36 26.32 23 11533 8668 50584900
Jaundice 30.85 26.32 34 11522 26395 50567173
Constipation 29.20 26.32 101 11455 185607 50407961
Feeding disorder 28.97 26.32 22 11534 10591 50582977
Drug hypersensitivity 28.26 26.32 11 11545 250999 50342569
Joint swelling 27.20 26.32 11 11545 245275 50348293
Ascites 27.03 26.32 37 11519 35824 50557744
Hepatic failure 26.92 26.32 35 11521 32248 50561320

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1889.48 23.25 564 14492 14195 29545276
Dysphonia 719.25 23.25 294 14762 18902 29540569
Decreased appetite 335.60 23.25 390 14666 144952 29414519
Metastases to lung 309.77 23.25 125 14931 7730 29551741
Off label use 300.03 23.25 541 14515 300259 29259212
Fatigue 273.74 23.25 536 14520 316285 29243186
Diarrhoea 201.22 23.25 488 14568 332210 29227261
Blister 199.63 23.25 125 14931 19781 29539690
Metastases to liver 175.90 23.25 96 14960 11760 29547711
Hypertension 155.72 23.25 240 14816 116374 29443097
Carcinoembryonic antigen increased 153.80 23.25 40 15016 584 29558887
Pain in extremity 134.53 23.25 218 14838 110215 29449256
Skin exfoliation 121.37 23.25 97 14959 22548 29536923
Blood bilirubin increased 118.81 23.25 114 14942 33779 29525692
Asthenia 106.88 23.25 294 14762 214956 29344515
Skin fissures 100.41 23.25 46 15010 3873 29555598
Neuropathy peripheral 98.57 23.25 149 14907 70878 29488593
Dry skin 96.39 23.25 86 14970 23221 29536250
Weight decreased 92.18 23.25 223 14833 150682 29408789
Stomatitis 85.75 23.25 100 14956 37013 29522458
Hyperkeratosis 85.73 23.25 39 15017 3230 29556241
Alpha 1 foetoprotein increased 84.20 23.25 25 15031 606 29558865
Tumour marker increased 78.94 23.25 23 15033 521 29558950
Ascites 76.91 23.25 94 14962 36525 29522946
Blood pressure increased 71.73 23.25 132 14924 73671 29485800
Hospitalisation 64.48 23.25 97 14959 45891 29513580
Hepatic function abnormal 64.08 23.25 89 14967 39170 29520301
Oral pain 58.85 23.25 44 15012 9263 29550208
Hepatic encephalopathy 57.68 23.25 50 15006 12985 29546486
Dehydration 52.06 23.25 152 14904 114596 29444875
Toxicity to various agents 50.68 23.25 13 15043 173648 29385823
Abdominal pain 48.29 23.25 165 14891 135192 29424279
Abdominal pain upper 48.16 23.25 100 14956 60893 29498578
Metastases to lymph nodes 47.34 23.25 28 15028 3989 29555482
Glossodynia 44.61 23.25 25 15031 3218 29556253
Aphonia 44.15 23.25 24 15032 2910 29556561
Drug interaction 40.90 23.25 25 15031 197360 29362111
Colorectal cancer metastatic 40.78 23.25 14 15042 547 29558924
Metastases to peritoneum 39.43 23.25 18 15038 1502 29557969
Dry mouth 37.96 23.25 51 15005 21733 29537738
Febrile neutropenia 37.71 23.25 6 15050 112234 29447237
Gastrointestinal stromal tumour 36.28 23.25 14 15042 766 29558705
Malaise 36.28 23.25 169 14887 159433 29400038
Drug ineffective 34.17 23.25 85 14971 363085 29196386
Colon cancer 33.12 23.25 29 15027 7626 29551845
Acute kidney injury 32.70 23.25 53 15003 265214 29294257
Condition aggravated 32.47 23.25 17 15039 146278 29413193
Constipation 30.56 23.25 127 14929 114033 29445438
Colon cancer metastatic 30.52 23.25 15 15041 1476 29557995
Proteinuria 29.07 23.25 38 15018 15766 29543705
Biliary obstruction 28.90 23.25 17 15039 2397 29557074
Hypotension 28.77 23.25 34 15022 194320 29365151
Angular cheilitis 28.49 23.25 8 15048 158 29559313
Cardiac arrest 27.80 23.25 5 15051 85586 29473885
Overdose 27.41 23.25 4 15052 79815 29479656
Colorectal cancer 27.34 23.25 15 15041 1852 29557619
Plantar erythema 26.34 23.25 6 15050 48 29559423
Gait inability 26.06 23.25 39 15017 18336 29541135
Protein induced by vitamin K absence or antagonist II increased 25.30 23.25 5 15051 18 29559453
Metastases to central nervous system 24.97 23.25 24 15032 7107 29552364
General physical health deterioration 24.88 23.25 111 14945 102746 29456725
Metastases to adrenals 24.25 23.25 11 15045 904 29558567
Adverse drug reaction 23.33 23.25 43 15013 23977 29535494

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 2704.01 21.41 817 24495 28002 64445418
Dysphonia 1038.01 21.41 457 24855 45925 64427495
Decreased appetite 532.64 21.41 601 24711 280688 64192732
Metastases to lung 470.01 21.41 189 25123 15075 64458345
Off label use 454.01 21.41 852 24460 631954 63841466
Fatigue 366.06 21.41 862 24450 747868 63725552
Diarrhoea 284.37 21.41 767 24545 721937 63751483
Metastases to liver 253.36 21.41 142 25170 23799 64449621
Blister 240.11 21.41 221 25091 80746 64392674
Asthenia 222.22 21.41 506 24806 427538 64045882
Neuropathy peripheral 214.41 21.41 247 25065 117278 64356142
Skin exfoliation 211.05 21.41 160 25152 44725 64428695
Hypertension 210.86 21.41 370 24942 258891 64214529
Carcinoembryonic antigen increased 200.54 21.41 59 25253 1814 64471606
Pain in extremity 198.35 21.41 394 24918 302691 64170729
Blood bilirubin increased 194.13 21.41 169 25143 57384 64416036
Hyperkeratosis 156.09 21.41 68 25244 6613 64466807
Weight decreased 154.81 21.41 344 24968 285395 64188025
Dry skin 150.30 21.41 139 25173 51022 64422398
Stomatitis 143.21 21.41 195 25117 109410 64364010
Skin fissures 142.34 21.41 73 25239 10233 64463187
Oral pain 122.58 21.41 95 25217 27398 64446022
Blood pressure increased 119.47 21.41 230 25082 172322 64301098
Dehydration 116.16 21.41 260 25052 216503 64256917
Hepatic function abnormal 113.51 21.41 133 25179 64180 64409240
Hospitalisation 99.99 21.41 135 25177 75072 64398348
Pyrexia 86.73 21.41 440 24872 558204 63915216
Alpha 1 foetoprotein increased 86.69 21.41 25 25287 715 64472705
Ascites 85.01 21.41 113 25199 61888 64411532
Toxicity to various agents 83.66 21.41 20 25292 363493 64109927
Tumour marker increased 83.48 21.41 36 25276 3414 64470006
Condition aggravated 82.80 21.41 22 25290 372404 64101016
Abdominal pain 80.26 21.41 287 25025 312088 64161332
Drug ineffective 77.68 21.41 132 25180 840115 63633305
Colon cancer 72.49 21.41 51 25261 12688 64460732
Dry mouth 67.75 21.41 100 25212 60318 64413102
Hepatic encephalopathy 67.24 21.41 60 25252 21006 64452414
Gait inability 65.56 21.41 82 25230 42286 64431134
Drug interaction 61.15 21.41 33 25279 362050 64111370
Abdominal pain upper 60.42 21.41 178 25134 174852 64298568
Colorectal cancer metastatic 59.82 21.41 20 25292 940 64472480
Rash 59.38 21.41 344 24968 458205 64015215
Platelet count decreased 59.27 21.41 172 25140 167539 64305881
Metastases to peritoneum 57.45 21.41 28 25284 3519 64469901
Mucosal inflammation 56.82 21.41 94 25218 62490 64410930
Colon cancer metastatic 56.36 21.41 23 25289 1900 64471520
Constipation 54.85 21.41 206 25106 229131 64244289
Plantar erythema 53.25 21.41 14 25298 281 64473139
Metastases to lymph nodes 49.83 21.41 35 25277 8682 64464738
Jaundice 46.93 21.41 75 25237 48437 64424983
Exercise tolerance decreased 46.52 21.41 32 25280 7678 64465742
Drug hypersensitivity 45.82 21.41 18 25294 237797 64235623
Erythema 44.67 21.41 168 25144 186902 64286518
Disseminated intravascular coagulation 42.85 21.41 58 25254 32290 64441130
Overdose 42.61 21.41 6 25306 159560 64313860
Hepatic failure 42.18 21.41 77 25235 55317 64418103
Infusion related reaction 42.06 21.41 7 25305 164460 64308960
Proteinuria 41.84 21.41 53 25259 27670 64445750
Acute kidney injury 40.04 21.41 72 25240 449168 64024252
Aspartate aminotransferase increased 39.57 21.41 120 25192 119668 64353752
Cardiac arrest 38.43 21.41 7 25305 154057 64319363
Gastrointestinal stromal tumour 38.38 21.41 16 25296 1395 64472025
Biliary obstruction 38.37 21.41 22 25290 3842 64469578
Hypotension 36.76 21.41 58 25254 380916 64092504
Weight increased 36.63 21.41 19 25293 213329 64260091
Skin toxicity 36.56 21.41 26 25286 6576 64466844
Colorectal cancer 36.50 21.41 20 25292 3201 64470219
Feeding disorder 35.72 21.41 34 25278 12915 64460505
Sinusitis 35.61 21.41 7 25305 145921 64327499
Palmoplantar keratoderma 35.22 21.41 11 25301 415 64473005
Febrile neutropenia 34.85 21.41 15 25297 187642 64285778
Fall 34.34 21.41 70 25242 416756 64056664
Pre-existing condition improved 34.12 21.41 22 25290 4740 64468680
Metastases to adrenals 34.09 21.41 14 25298 1175 64472245
Gastrointestinal perforation 33.88 21.41 23 25289 5401 64468019
Rectal cancer 33.40 21.41 18 25294 2788 64470632
Ammonia increased 33.04 21.41 25 25287 6952 64466468
Decreased activity 32.40 21.41 25 25287 7155 64466265
Protein induced by vitamin K absence or antagonist II increased 32.27 21.41 6 25306 20 64473400
Pain of skin 32.08 21.41 28 25284 9519 64463901
Arthropathy 31.26 21.41 5 25307 120962 64352458
Therapeutic product ineffective 30.84 21.41 14 25298 1499 64471921
Adverse drug reaction 30.65 21.41 60 25252 45404 64428016
Food refusal 30.44 21.41 10 25302 445 64472975
Joint swelling 30.38 21.41 24 25288 215358 64258062
Hypersomnia 30.23 21.41 38 25274 19679 64453741
Nasopharyngitis 30.06 21.41 20 25292 196053 64277367
Gait disturbance 29.67 21.41 140 25172 172015 64301405
Death 28.54 21.41 302 25010 482403 63991017
Aphonia 28.20 21.41 25 25287 8672 64464748
Oral hyperaesthesia 27.37 21.41 4 25308 0 64473420
Pancytopenia 27.33 21.41 11 25301 143298 64330122
Intestinal obstruction 27.06 21.41 50 25262 36236 64437184
Hyperbilirubinaemia 26.54 21.41 37 25275 21168 64452252
Liver disorder 26.28 21.41 62 25250 53289 64420131
Metastasis 26.07 21.41 20 25292 5675 64467745
Tumour rupture 24.41 21.41 8 25304 353 64473067
Malaise 24.38 21.41 250 25062 395997 64077423
Pneumonia 24.34 21.41 125 25187 559451 63913969
Syncope 24.27 21.41 16 25296 157619 64315801
Cancer pain 24.12 21.41 17 25295 4240 64469180
Treatment failure 23.91 21.41 8 25304 116808 64356612
Protein urine present 23.73 21.41 23 25289 8933 64464487
Hepatic lesion 23.53 21.41 19 25293 5805 64467615
Abnormal loss of weight 23.46 21.41 21 25291 7379 64466041
Anxiety 23.42 21.41 27 25285 202622 64270798
Depression 22.75 21.41 23 25289 183268 64290152
Intestinal metastasis 22.57 21.41 7 25305 258 64473162
Asthma 22.33 21.41 5 25307 95220 64378200
Hepatic pain 22.21 21.41 15 25297 3493 64469927
Osteosarcoma metastatic 22.16 21.41 5 25307 51 64473369
Cardiac failure congestive 21.86 21.41 12 25300 130568 64342852
Metastases to abdominal cavity 21.85 21.41 8 25304 493 64472927
Hypersensitivity 21.82 21.41 27 25285 196425 64276995
Angular cheilitis 21.80 21.41 8 25304 496 64472924
Skin disorder 21.73 21.41 39 25273 27641 64445779

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:50908 agente hepatotoxico

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Metastasis from malignant tumor of colon indication 314998002
Gastrointestinal stromal tumor indication 420120006 DOID:9253




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.41 acidic
pKa2 11.83 acidic
pKa3 12.52 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
40MG STIVARGA BAYER HLTHCARE N203085 Sept. 27, 2012 RX TABLET ORAL 8680124 June 2, 2030 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG STIVARGA BAYER HLTHCARE N203085 Sept. 27, 2012 RX TABLET ORAL April 27, 2024 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Serine/threonine-protein kinase B-raf Kinase INHIBITOR IC50 7.55 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 7.90 IUPHAR CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.12 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase IC50 8.21 CHEMBL
Breakpoint cluster region protein Kinase Kd 6.13 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 6.08 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase IC50 8.82 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase IC50 7.09 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.90 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase IC50 8.82 CHEMBL
Angiopoietin-1 receptor Kinase IC50 8.82 CHEMBL
LIM domain kinase 1 Kinase Kd 6.21 CHEMBL
Fibroblast growth factor receptor 1 Kinase IC50 8.82 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.41 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 5.72 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.95 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.15 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.68 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.12 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.45 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme INHIBITOR IC50 9.30 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 6.17 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 6.14 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 6.56 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.38 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 8.15 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 6.33 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 5.74 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 6.43 CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 8.82 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 8.82 CHEMBL
Vascular endothelial growth factor receptor 3 Kinase IC50 8.82 CHEMBL

External reference:

IDSource
D10137 KEGG_DRUG
4031721 VANDF
CHEBI:68647 CHEBI
CHEMBL1946170 ChEMBL_ID
C559147 MESH_SUPPLEMENTAL_RECORD_UI
5891 IUPHAR_LIGAND_ID
DB08896 DRUGBANK_ID
MGN125FS9D UNII
11167602 PUBCHEM_CID
1312397 RXNORM
193440 MMSL
28887 MMSL
d07913 MMSL
014656 NDDF
702804006 SNOMEDCT_US
703808002 SNOMEDCT_US
C2980094 UMLSCUI
1019206-88-2 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Stivarga HUMAN PRESCRIPTION DRUG LABEL 1 50419-171 TABLET, FILM COATED 40 mg ORAL NDA 29 sections